Session Title: Quick Fire Free Paper Session 04
Session Date/Time: Sunday 29/09/2013 | 11:00-13:00
Paper Time: 11:45
Venue: Hall C (Level 1)
First Author: H.Schilling GERMANY
To examine the outcome of treating cystoid macular oedema following cataract surgery with Ozurdex after failure of conventional therapy.
The study was conducted at the Eye-Clinic of the St.-Johannes-Hospital Dortmund, Germany.
Prospective interventional case series of 6 eyes of 6 patients who did not show any response after treatment with a daily dosage of 3 x 250 mg acetacolamide and topical non-steroidal antiinflammatory drugs for 4 weeks. The visul acuity was measured by ETDRS-charts at baseline and every 4 weeks after the injection of the implant. The central thickness of the retina was measured by SD-OCT at every visit which consisted in a full routine examination. Exclusion criteria were: previous operations on the the same eye, known steroid responder, known glaucoma and vitreomacular traction as detected in the SD-OCT. The implant containing 700 µg dexamethasone was injected as recommended by the manufacturer.
After a minimum follow-up of 2 months the visual acuity had increased in all patients with a mean of 23 letters. The central (foveal) thickness decreased by 307,8 µm in average. The intraocular pressure (IOP) raised from a mean of 13 mm Hg at baseline to a mean of 17,8 mm Hg. An elevation of IOP beyond 21 mm Hg occurred in only one patient which could succcessfully treated with topical antiglaucomateous medication.
The intravitreal injection of Ozurdex represents a highly effective therapeutical option in cases of Irvine-Gass-Syndrome which are refractory to conventional therapy. According to our observations the effect is stable for at least 2 months after application. No financial interest."